ReviewStem cells (Dayton, Ohio)2010
Concise review: Kidney stem/progenitor cells: differentiate, sort out, or reprogram?
Review in Stem cells (Dayton, Ohio), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 100 citations in OpenAlex.
- Clinical efficacy and safety of allogeneic adipose-derived stem cells ELIXCYTE in chronic kidney disease: a phase I/II study.Stem cells translational medicine · 2026Trial
- HmmrResearch (Washington, D.C.) · 2026Article
- Human fetal kidney organoids model early human nephrogenesis and Notch-driven cell fate.The EMBO journal · 2025Article
- A high-definition spatiotemporal transcriptomic atlas of mammalian kidney development.Innovation (Cambridge (Mass.)) · 2025Article
- Expression of ENL YEATS domain tumor mutations in nephrogenic or stromal lineage impairs kidney development.Nature communications · 2025Article
- Role of mitochondria in endogenous renal repair.Clinical science (London, England : 1979) · 2024Review
- OCT4 induces long-lived dedifferentiated kidney progenitors poised to redifferentiate in 3D kidney spheroids.Molecular therapy. Methods & clinical development · 2023Article
- Spatio-Temporal Expression Pattern of CAKUT Candidate GenesBiomolecules · 2023Article
- Mechanical force drives the initial mesenchymal-epithelial interaction during skin organoid development.Theranostics · 2023Article
- Reprogramming of three-dimensional microenvironments for in vitro hair follicle induction.Science advances · 2022Article
- The genetic basis of congenital anomalies of the kidney and urinary tract.Pediatric nephrology (Berlin, Germany) · 2022Review
- Allogeneic adipose tissue-derived stem cells ELIXCYTEJournal of cellular and molecular medicine · 2022Article
- Potential renal stem/progenitor cells identified by in vivo lineage tracing.American journal of physiology. Renal physiology · 2022Review
- Cellular milieu in clear cell renal cell carcinoma.Frontiers in oncology · 2022Review
- Congenital Anomalies of the Kidney and Urinary Tract and Adulthood risk of Urinary Tract Cancer.Kidney international reports · 2021Article
- Current Methods for the Isolation of Urinary Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Successful Introduction of Human Renovascular Units into the Mammalian Kidney.Journal of the American Society of Nephrology : JASN · 2020Article
- Combining Kidney Organoids and Genome Editing Technologies for a Better Understanding of Physiopathological Mechanisms of Renal Diseases: State of the Art.Frontiers in medicine · 2020Review
- Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury.Cell transplantation · 2019Article
- Recapitulating kidney development: Progress and challenges.Seminars in cell & developmental biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End-stage renal disease (ESRD) is defined as the inability of the kidneys to remove waste products and excess fluid from the blood. ESRD progresses from earlier stages of chronic kidney disease (CKD) and occurs when the glomerular filtration rate (GFR) is below 15 ml/minute/1.73 m(2). CKD and ESRD are dramatically rising due to increasing aging population, population demographics, and the growing rate of diabetes and hypertension. Identification of multipotential stem/progenitor populations in mammalian tissues is important for therapeutic applications and for understanding developmental processes and tissue homeostasis. Progenitor populations are ideal targets for gene therapy, cell transplantation, and tissue engineering. The demand for kidney progenitors is increasing due to severe shortage of donor organs. Because dialysis and transplantation are currently the only successful therapies for ESRD, cell therapy offers an alternative approach for kidney diseases. However, this approach may be relevant only in earlier stages of CKD, when kidney function and histology are still preserved, allowing for the integration of cells and/or for their paracrine effects, but not when small and fibrotic end-stage kidneys develop. Although blood- and bone marrow-derived stem cells hold a therapeutic promise, they are devoid of nephrogenic potential, emphasizing the need to seek kidney stem cells beyond known extrarenal sources. Moreover, controversies regarding the existence of a true adult kidney stem cell highlight the importance of studying cell-based therapies using pluripotent cells, progenitor cells from fetal kidney, or dedifferentiated/reprogrammed adult kidney cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.